Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in Am J Nephrol Retrieve available abstracts of 11 articles: HTML format

Single Articles

September 2025
1. FERNANDEZ-FERNANDEZ B, Hasegawa T, Saruta Y, Li Guan Y, et al
   Plasma IL-22 predicts progression of early diabetic kidney disease.
   Am J Nephrol. 2025 Sep 8:1-21. doi: 10.1159/000547738.
   PubMed     Abstract available
   
   
   June 2025
2. LV L, Zheng W, Hu M, Cheing GLY, et al
   The role of cell-cell communication in renal damage and the therapeutic targeting of diabetic kidney disease.
   Am J Nephrol. 2025 Jun 13:1-22. doi: 10.1159/000546739.
   PubMed     Abstract available
   
   
   January 2025
3. KITAMURA H, Tanaka S, Hiyamuta H, Tsuruya K, et al
   Associations of Causes of Chronic Kidney Disease with Disease Progression and Mortality: Insights from the Fukuoka Kidney disease Registry (FKR) Study.
   Am J Nephrol. 2025 Jan 8:1-21. doi: 10.1159/000543201.
   PubMed     Abstract available
   
   
   
4. MCDONNELL T, Kalra PA, Vuilleumier N, Cockwell P, et al
   The Impact of Primary Renal Diagnosis on Prognosis and the Varying Predictive Power of Albuminuria in the NURTuRE-CKD Study.
   Am J Nephrol. 2025;56:1-12.
   PubMed     Abstract available
   
   
   November 2024
5. FERREIRA JP, Oliveira AC, Vasques-Novoa F, Leite AR, et al
   Mineralocorticoid receptor antagonist combined with a SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: a meta-analysis of randomized trials.
   Am J Nephrol. 2024 Nov 7:1-13. doi: 10.1159/000541686.
   PubMed     Abstract available
   
   
   October 2024
6. SHIAO CC, Chiu CW, Chang YM, Liu MC, et al
   Comprehensive Evaluation of the Cardiovascular Protective Effects of SGLT2 Inhibitors in Patients with Advanced Chronic Kidney Disease: A Real-World Evidence.
   Am J Nephrol. 2024 Oct 21:1-28. doi: 10.1159/000542132.
   PubMed     Abstract available
   
   
   May 2024
7. MOLONEY BM, Chertow GM, Mc Causland FR
   Association of Diabetes with Changes in Blood Pressure during Hemodialysis: A Secondary Analysis of the Frequent Hemodialysis Network Daily Trial.
   Am J Nephrol. 2024 May 23. doi: 10.1159/000539451.
   PubMed     Abstract available
   
   
   February 2024
8. STAVAS J, Silva AL, Wooldridge TD, Aqeel A, et al
   Rilparencel (Renal Autologous Cell Therapy-REACT(R)) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing Triggers.
   Am J Nephrol. 2024 Feb 29. doi: 10.1159/000537942.
   PubMed     Abstract available
   
   
   
9. MAKAWI AT, Tawfik YMK, Dixon DL, McMahon GM, et al
   Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease.
   Am J Nephrol. 2024 Feb 28:1-4. doi: 10.1159/000536540.
   PubMed    
   
   
   
10. CROUCH E, Yell N, Herbert L, Browne T, et al
    Availability and quality of dialysis care in rural versus urban U.S. counties.
    Am J Nephrol. 2024 Feb 11. doi: 10.1159/000537763.
    PubMed     Abstract available
    
    
    January 2024
11. TUTTLE KR, Rossing P, Hauske SJ, Cronin L, et al
    Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease.
    Am J Nephrol. 2024;55:262-272.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.